CN116637072A - 一种布洛芬纳米前药包载抗肿瘤药物的双药共递送纳米胶束及其制备方法和应用 - Google Patents
一种布洛芬纳米前药包载抗肿瘤药物的双药共递送纳米胶束及其制备方法和应用 Download PDFInfo
- Publication number
- CN116637072A CN116637072A CN202310499610.XA CN202310499610A CN116637072A CN 116637072 A CN116637072 A CN 116637072A CN 202310499610 A CN202310499610 A CN 202310499610A CN 116637072 A CN116637072 A CN 116637072A
- Authority
- CN
- China
- Prior art keywords
- nano
- ibuprofen
- prodrug
- drug
- self
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960001680 ibuprofen Drugs 0.000 title claims abstract description 93
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 title claims abstract description 91
- 229940002612 prodrug Drugs 0.000 title claims abstract description 90
- 239000000651 prodrug Substances 0.000 title claims abstract description 90
- 239000003814 drug Substances 0.000 title claims abstract description 49
- 229940079593 drug Drugs 0.000 title claims abstract description 48
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 44
- 229940041181 antineoplastic drug Drugs 0.000 title claims abstract description 40
- 239000000693 micelle Substances 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000000412 dendrimer Substances 0.000 claims abstract description 29
- 229920000736 dendritic polymer Polymers 0.000 claims abstract description 29
- 238000011068 loading method Methods 0.000 claims abstract description 8
- 239000002105 nanoparticle Substances 0.000 claims abstract description 8
- 238000001338 self-assembly Methods 0.000 claims abstract description 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 39
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 20
- 239000003960 organic solvent Substances 0.000 claims description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 229960004679 doxorubicin Drugs 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 17
- 230000008569 process Effects 0.000 claims description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 10
- 230000009977 dual effect Effects 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 238000010898 silica gel chromatography Methods 0.000 claims description 7
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 6
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000007098 aminolysis reaction Methods 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 239000012046 mixed solvent Substances 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000004185 ester group Chemical group 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 3
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 3
- 238000010791 quenching Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 238000012650 click reaction Methods 0.000 claims description 2
- 239000007822 coupling agent Substances 0.000 claims description 2
- 239000003480 eluent Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 239000012074 organic phase Substances 0.000 claims description 2
- 230000000171 quenching effect Effects 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 239000000376 reactant Substances 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 abstract description 15
- 230000004663 cell proliferation Effects 0.000 abstract description 8
- 210000004881 tumor cell Anatomy 0.000 abstract description 7
- 230000000259 anti-tumor effect Effects 0.000 abstract description 6
- 230000002209 hydrophobic effect Effects 0.000 abstract description 6
- 238000012377 drug delivery Methods 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 239000003937 drug carrier Substances 0.000 abstract description 2
- 206010028980 Neoplasm Diseases 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 230000000694 effects Effects 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 7
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 4
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 108010087230 Sincalide Proteins 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 150000001540 azides Chemical group 0.000 description 3
- 239000012876 carrier material Substances 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 229940044683 chemotherapy drug Drugs 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000001553 co-assembly Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/595—Polyamides, e.g. nylon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种布洛芬纳米前药包载抗肿瘤药物的双药共递送纳米胶束及其制备方法和应用,由两亲性树状分子布洛芬自组装纳米前药包载抗肿瘤药物形成双药共递送纳米胶束,其中两亲性树状分子布洛芬自组装纳米前药具有式I、式II所示结构:本发明还具体公开了该布洛芬纳米前药包载抗肿瘤药物的双药共递送纳米胶束的制备方法及其在制备抗肿瘤药物靶向递送及抑制恶性肿瘤细胞增殖的靶向抗肿瘤药物中的应用。本发明中前药分子具有两亲性,通过自组装形成的纳米粒,可作为药物载体递送疏水性药物,促进药物的递送效率,进而显示出比母体药物更高的抗肿瘤活性。
Description
技术领域
本发明属于药物递送系统技术领域,具体涉及一种布洛芬纳米前药包载抗肿瘤药物的双药共递送纳米胶束及其制备方法和应用。
背景技术
随着科学技术的进步和发展,研究者对恶性肿瘤的发生、进展、转移机制的认识日渐深入,探索发现了多种针对恶性肿瘤治疗的创新疗法,但癌症患者的总体生存率却未得到明显提高(Biomaterials2021,271,120737.)。可见癌症治疗仅依靠传统单一的治疗方法很难获得理想的治疗效果。例如,化疗药物被用于预防癌症复发、抑制转移、加速肿瘤缩小等各个阶段,但是这类药物因为在体内分布缺乏选择性同时易产生耐药,而易引发譬如炎症感染等多种毒副作用,让癌症患者饱受病痛折磨,而疗效却差强人意。
近来研究发现恶性肿瘤的发生发展与感染及慢性刺激炎症密切相关,包括肿瘤的引发、进展、侵袭和远端转移在内的各个阶段,炎症均起着重要作用(AnticancerRes,2020,40,1503.)。而布洛芬是一种具有显著抗炎、解热和镇痛作用的非甾体抗炎药。多项流行病学研究表明,长期或定期使用非甾体抗炎药可以降低恶性肿瘤的发生率(Annu.Rev.Med.2000,51,511.Carcinogenesis,2013,34,620.)。布洛芬类的非甾体抗炎药主要通过抑制环氧合酶(COX)活性发挥抗肿瘤作用,尤其是对COX-2的抑制。COX-2在许多炎症及肿瘤组织中过表达,并在肿瘤发生中发挥重要作用(Sci WorldJ.2001,1,808.)。Andrews等人评估了五种非甾体抗炎药对前列腺癌症细胞的抑制作用,他们发现,在所有测试的非甾体抗炎药中,布洛芬可以更有效地抑制肿瘤细胞增殖和诱导细胞凋亡(CancerChemother.Pharmacol.2002,50,277.)。此外,布洛芬可下调血管生成调节因子VEGF的表达,并抑制血管生成。同时布洛芬具有镇痛作用,这是其在癌症临床治疗中的巨大优势之一(TumorBiol.2015,36,3237.)。因此,抗癌药物与布洛芬类非甾体抗炎药的组合有望成为治疗恶性肿瘤的有效策略,亟需构建一种可高效联合递送抗癌药物与非甾体类抗炎药的递送系统,以充分发挥两类药物的协同治疗作用。
基于纳米技术借助纳米载体构建的纳米药物已经成为极具应用潜力的全身抗肿瘤药物递送的有效策略。其中近年来新兴的基于前体药物的自组装前药纳米递送系统将前体药物和纳米技术的优点结合到一起,以其稳定性好、载药量高、毒副作用小等优势,已成为药物递送领域的热点(Adv.DrugDeliv.Rev.2021,179,114027.)。例如,专利文献CN111407729A中公布了一种布洛芬聚合物前药与阿霉素共组装纳米药物,先通过将布洛芬键连在聚合物聚乙二醇-聚乳酸表面得到布洛芬聚合物前药,再将阿霉素负载于布洛芬聚合物前药上得到布洛芬聚合物前药与阿霉素共组装纳米药物。该专利文献的技术方案中聚合物载体材料的分子量及其分布控制相对困难,不易重复,且生产成本较高,产率相对较低,在一定程度上限制了其进一步推广应用。
发明内容
鉴于现有癌症的治疗及共组装纳米药物存在的技术问题,本发明提供了一种布洛芬纳米前药包载抗肿瘤药物的双药共递送纳米胶束及其制备方法,该双药共递送纳米胶束能够用于制备抗肿瘤药物靶向递送及抑制恶性肿瘤细胞增殖的靶向抗肿瘤药物。
本发明所述双药共递送纳米胶束中自组装布洛芬纳米前药的亲水链段为聚酰胺树状分子,疏水链段为烃基长链或聚乙二醇;亲水链段和疏水链段通过“叠氮-炔”点击化学反应连接,兼具抗炎和抗肿瘤作用的布洛芬通过化学键修饰到树状分子表面形成两亲性自组装布洛芬纳米前药;两亲性自组装布洛芬纳米前药能够在水溶液中自组装形成纳米胶束,该纳米胶束可高效地负载抗肿瘤药物阿霉素,并促进负载抗肿瘤药物进入肿瘤细胞,最终表现出显著高于游离阿霉素的抗肿瘤细胞增殖活性;并且该基于树状分子的自组装纳米前药的结构明确,合成便捷。
本发明为解决上述技术问题采用如下技术方案,一种布洛芬纳米前药包载抗肿瘤药物的双药共递送纳米胶束,其特征在于:由两亲性树状分子布洛芬自组装纳米前药包载抗肿瘤药物形成双药共递送纳米胶束,其中两亲性树状分子布洛芬自组装纳米前药具有式I、式II所示结构:
其中R为烃基。
进一步限定,所述抗肿瘤药物为阿霉素。
进一步限定,所述式I、式II中R为-CH2CH2(CH2)nCH3,n为2~500之间的任意整数。
一种布洛芬纳米前药包载抗肿瘤药物的双药共递送纳米胶束的制备方法,其特征在于具体步骤为:(1)合成末端氨基修饰的两亲性树状分子;(2)将布洛芬分子接枝接到步骤(1)合成的两亲性树状分子表面得到含炔基的布洛芬-树状分子前药;(3)使用Click反应,将末端叠氮的烃基长链连接到步骤(2)合成的布洛芬-树状分子前药末端得到两亲性树状分子布洛芬自组装纳米前药;(4)将步骤(3)合成的两亲性树状分子布洛芬自组装纳米前药在水溶液中自组装形成纳米胶束;(5)将步骤(4)得到的纳米胶束包载抗肿瘤药物得到布洛芬纳米前药包载抗肿瘤药物的双药共递送纳米胶束。
进一步限定,步骤(1)的具体过程为:利用含酯基的一代或高代树状分子与乙二胺在有机溶剂中发生胺解反应合成末端氨基修饰的两亲性树状分子,上述胺解反应通过常规条件即可实现。该树状分子结构中的氨基基团可用于连接布洛芬。
其中,对于一代氨基末端的两亲性树状分子的合成,具体反应式如下式III所示。
第一步合成末端氨基修饰的两亲性树状分子,具体为利用乙二胺与酯基之间的还原胺反应得到。所用树状分子为一代树状分子或二代树状分子,该树状分子与乙二胺的摩尔比为1:5~1:80,胺解反应时间为5~168h。上述反应优选在常温条件下进行,有机溶剂为甲醇,产物通过沉降或透析,冻干后得到。
进一步限定,步骤(2)的具体过程为:利用末端氨基修饰的树状分子与布洛芬之间发生酰化反应合成两亲性树状分子布洛芬自组装纳米前药,上述酰化反应通过常规反应即可实现。该前药分子结构中酰胺键在体内酶催化下可断裂。反应式如式IV所示。
第二步合成两亲性树状分子布洛芬自组装纳米前药,以布洛芬和末端氨基修饰的两亲性树状分子为原料,低温条件下于有机溶剂中发生取代反应,硅胶柱层析分离纯化得到两亲性树状分子布洛芬自组装纳米前药。所述有机溶剂为二氯甲烷、四氢呋喃或DMF中的一种或多种;末端氨基修饰的两亲性树状分子与布洛芬的摩尔比为1:2~1:5;反应温度为0~30℃;反应时间为3~24h。具体过程为:向反应瓶中加入偶联剂EDCl和HOBt、反应物末端氨基修饰的两亲性树状分子和布洛芬以及有机溶剂,于室温搅拌反应,最后用3~10倍量的蒸馏水淬灭反应,有机溶剂萃取,收集有机相,干燥,过滤,浓缩,硅胶柱层析分离,洗脱液为二氯甲烷/甲醇混合溶剂,最终得到两亲性树状分子布洛芬自组装纳米前药。
步骤(3)具体过程和产物结构如下所示。其中,式V是一代布洛芬树状分子前药的制备反应。
其中,n是亚甲基的重复单元数,n为2~500之间的任意整数。
进一步限定,步骤(3)的具体过程为:利用“叠氮-炔”点击化学反应,将两亲性树状分子布洛芬自组装纳米前药与末端叠氮的烃基长链在溶剂中于30~80℃反应得到两亲性树状分子布洛芬自组装纳米前药。其中两亲性树状分子布洛芬自组装纳米前药与叠氮末端的烃基长链的摩尔比为1:1.0~2:1.0,优选为1:1.0~1.5:1.0;反应温度优选为30~60℃;溶剂为四氢呋喃与水的混合溶剂;反应时间为1~8h,优选为3~5h;硅胶柱层析得到纯化产物。
进一步限定,步骤(4)的具体过程为:将两亲性树状分子布洛芬自组装纳米前药溶于有机溶剂形成浓度为1.0~25.0mg/mL的两亲性树状分子布洛芬自组装纳米前药有机溶液,随后将两亲性树状分子布洛芬自组装纳米前药有机溶液滴加到水溶液中,再除去有机溶剂得到含有平均粒径为7-400nm纳米颗粒的自组装纳米胶束。其中两亲性树状分子布洛芬自组装纳米前药有机溶液的浓度优选为1.0~10.0mg/mL;自组装纳米胶束中纳米颗粒的平均粒径优选为6-100nm。
本发明所述的布洛芬纳米前药包载抗肿瘤药物的双药共递送纳米胶束在制备抗肿瘤药物靶向递送及抑制恶性肿瘤细胞增殖的靶向抗肿瘤药物中的应用。
本发明借助于表面基团丰富、易于修饰、结构可控的两亲性树状分子,通过酸酶敏感的酰胺键使其与兼具抗炎和抗癌作用的药物布洛芬进行偶联,制备得到两亲性树状分子布洛芬纳米前药,该布洛芬纳米前药具备两亲性,在一定条件下可自组装形成纳米胶束。布洛芬在所得的纳米前药中既充当载体又是药物,而且该纳米前药还可以用作载体递送其它疏水性药物,便捷实现联合治疗。该类纳米前药在制备抗肿瘤药物领域具有广阔的应用前景。
与现有技术相比,本发明的有益效果如下:
(1)作为载体的树状分子结构可控,合成简易,表面基团丰富,有利于便捷构建两亲性纳米前药。
(2)本发明的树状分子布洛芬前药在水溶液中可自组装形成纳米颗粒,药物的负载效率高,结构稳定,利于推广。
(3)该前药分子具有两亲性,通过自组装形成的纳米粒,可作为药物载体递送疏水性药物,促进药物的递送效率,进而显示出比母体药物更高的抗肿瘤活性。
(4)本发明提供了一种布洛芬自组装纳米前药的制备方法,可获得高载药量的智能型纳米药物,在肿瘤联合治疗方面有广阔的应用前景。
附图说明
图1为实施例1产物的1H NMR;
图2为实施例2产物的质谱图;
图3为实施例3产物的质谱图;
图4为实施4代表性布洛芬自组装纳米药物C18-2iBu的粒径分布;
图5为树状分子-布洛芬自组装纳米前药C18-2iBu及其负载化疗药物阿霉素的双药共递送纳米胶束C18-2iBu/DOX和游离阿霉素对肿瘤细胞的抗增殖活性;
图6为树状分子-布洛芬纳米前药负载化疗药物阿霉素的双药共递送纳米胶束C18-2iBu/DOX和游离阿霉素DOX进入细胞速率研究。
具体实施方式
以下通过实施例对本发明的上述内容做进一步详细说明,但不应该将此理解为本发明上述主题的范围仅限于以下的实施例,凡基于本发明上述内容实现的技术均属于本发明的范围。
以下实施例所述制备过程,所采用的所有化学试剂如无特别标注均为分析纯。
实施例1
一代氨基末端树状分子的制备:
称取酯基末端的树状分子460mg(2.0mmol)溶于甲醇中,随后加入乙二胺2.5mL(37mmol),于室温发生胺解反应直至反应物消耗完全,减压除去溶剂,沉降纯化,抽干得到粘稠状液体540mg,产率为95.3%。
实施例2
含炔键的布洛芬前药的合成:
称取EDCl 384mg(2.0mmol)、HOBt 273mg(2.0mmol)、氨基末端的树状分子140mg(0.5mmol)和布洛芬226mg(1.1mmol),溶于5mL有机溶剂二氯甲烷中,于室温反应,点板检测反应进程,反应完全后,加入20mL蒸馏水淬灭反应,以二氯甲烷萃取,萃取3次,合并萃取液,无水硫酸钠干燥,减压浓缩,硅胶柱层析分离,二氯甲烷/甲醇混合溶剂梯度洗脱,得到白色固体222mg,产率68%。
实施例3
一代以C18长链为疏水部分的树状分子-布洛芬两亲性前药的制备:
称取含炔键的布洛芬前药(96mg,0.14mmol)、CuSO4·5H2O(2.9mg,10mol%)及抗坏血酸钠(2.3mg,10mol%),随后依次加入末端叠氮修饰的烃基长链及四氢呋喃和水,于60℃搅拌反应,点板检测反应,反应停止以后,萃取,旋干,硅胶柱层析,二氯甲烷/甲醇混合溶剂梯度洗脱,得到白色固体75mg,产率71%。
实施例4
两亲性树状分子-布洛芬前药纳米粒的制备及表征:
将实施例3中的产物溶于有机溶剂四氢呋喃或丙酮中,随后将含有两亲性前药的有机溶剂滴加到水溶液中,再除去有机溶剂得到纳米前药的胶束溶液。
采用马尔文粒度分析仪,以动态光散射法测定纳米粒的粒径分布,测定前用去离子水稀释样品至适当浓度。如图4所示,C18-2iBu可自发在水溶液中自组装形成稳定的纳米胶束,适合靶向递送药物。
实施例5
树状分子布洛芬自组装纳米前药,布洛芬自组装纳米前药包载阿霉素得到的双药共递送纳米胶束,及游离阿霉素的抗肿瘤细胞增殖活性:
利用CCK8法分别测定树状分子布洛芬自组装纳米前药C18-2iBu,布洛芬自组装纳米前药包载阿霉素得到的双药共递送纳米胶束C18-2iBu/DOX,及游离阿霉素DOX对人胰腺癌细胞SW1990的抑制情况。将细胞接种到96孔板中,并于含10wt%FBS的DMEM培养基中过夜培养。弃去培养基,每孔加入,单独或含有不同化合物的新鲜培养液,继续培养72h。用含有10μL CCK-8溶液的新鲜培养基100μL替换含药物培养基,37℃继续孵育1h;最后通过全自动酶标仪于450nm波长下检测溶液吸光度值。使用未经处理的细胞、CCK-8溶液而没有加入药物溶液的孔作为对照组,使用加入相应量细胞培养液和CCK-8溶液但没有加入细胞的孔作为空白对照,每个浓度设置4个复孔。细胞增值活力计算公式如下:
细胞增值活力(%)=[A(加药)-A(空白)]/[A(0加药)-A(空白)]×100
注:A(加药):具有细胞、CCK8溶液和药物溶液的孔的吸光度;A(0加药):具有细胞、CCK8溶液而没有药物溶液的孔的吸光度;A(空白):具有培养基和CCK8溶液而没有药物的孔的吸光度。所有实验一式三份,独立重复三次。
实施例6
布洛芬纳米前药包载阿霉素的双药共递送纳米胶束及游离阿霉素的细胞摄入:
利用流式细胞术评估纳米胶束在肿瘤细胞中的摄入情况。将SW1990细胞接种在6孔细胞培养板中,37℃过夜培养。随后将6孔板中培养基置换成含药物的培养基,作用时间分别为10min、20min、30min、1h、2h和4h。到达相应的时间以后,细胞被胰酶消化后,使用1×PBS缓冲液冲洗,收集细胞,流式细胞仪分析药物在细胞中的摄入情况。
以上实施例描述了本发明的基本原理、主要特征及优点,本行业的技术人员应该了解,本发明不受上述实施例的限制,上述实施例和说明书中描述的只是说明本发明的原理,在不脱离本发明原理的范围下,本发明还会有各种变化和改进,这些变化和改进均落入本发明保护的范围内。
Claims (10)
1.一种布洛芬纳米前药包载抗肿瘤药物的双药共递送纳米胶束,其特征在于:由两亲性树状分子布洛芬自组装纳米前药包载抗肿瘤药物形成双药共递送纳米胶束,其中两亲性树状分子布洛芬自组装纳米前药具有式I、式II所示结构:
其中R为烃基。
2.根据权利要求1所述的布洛芬纳米前药包载抗肿瘤药物的双药共递送纳米胶束,其特征在于:所述抗肿瘤药物为阿霉素。
3.根据权利要求1所述的布洛芬纳米前药包载抗肿瘤药物的双药共递送纳米胶束,其特征在于:所述式I、式II中R为-CH2CH2(CH2)nCH3,n为2~500之间的任意整数。
4.一种权利要求1~3中任意一项所述的布洛芬纳米前药包载抗肿瘤药物的双药共递送纳米胶束的制备方法,其特征在于具体步骤为:(1)合成末端氨基修饰的两亲性树状分子;(2)将布洛芬分子接枝接到步骤(1)合成的两亲性树状分子表面得到含炔基的布洛芬-树状分子前药;(3)使用Click反应,将末端叠氮的烃基长链连接到步骤(2)合成的布洛芬-树状分子前药末端得到两亲性树状分子布洛芬自组装纳米前药;(4)将步骤(3)合成的两亲性树状分子布洛芬自组装纳米前药在水溶液中自组装形成纳米胶束;(5)将步骤(4)得到的纳米胶束包载抗肿瘤药物得到布洛芬纳米前药包载抗肿瘤药物的双药共递送纳米胶束。
5.根据权利要求4所述的布洛芬纳米前药包载抗肿瘤药物的双药共递送纳米胶束的制备方法,其特征在于步骤(1)的具体过程为:利用含酯基的一代或高代树状分子与乙二胺在有机溶剂中于常温发生胺解反应合成末端氨基修饰的两亲性树状分子,其中树状分子与乙二胺的摩尔比为1:5~1:80。
6.根据权利要求4所述的布洛芬纳米前药包载抗肿瘤药物的双药共递送纳米胶束的制备方法,其特征在于步骤(2)的具体过程为:以布洛芬和末端氨基修饰的两亲性树状分子为原料,在有机溶剂中于0~30℃发生取代反应,硅胶柱层析分离纯化得到两亲性树状分子布洛芬自组装纳米前药,其中有机溶剂为二氯甲烷、四氢呋喃或DMF中的一种或多种,末端氨基修饰的两亲性树状分子与布洛芬的摩尔比为1:2~1:5。
7.根据权利要求6所述的布洛芬纳米前药包载抗肿瘤药物的双药共递送纳米胶束的制备方法,其特征在于步骤(2)的具体过程为:向反应容器中加入偶联剂EDCl和HOBt、反应物末端氨基修饰的两亲性树状分子和布洛芬以及有机溶剂,于室温搅拌反应,再用3~10倍量的蒸馏水淬灭反应,有机溶剂萃取,收集有机相,干燥,过滤,浓缩,硅胶柱层析分离,洗脱液为二氯甲烷/甲醇混合溶剂,最终得到两亲性树状分子布洛芬自组装纳米前药。
8.根据权利要求4所述的布洛芬纳米前药包载抗肿瘤药物的双药共递送纳米胶束的制备方法,其特征在于步骤(3)的具体过程为:利用“叠氮-炔”点击化学反应,将两亲性树状分子布洛芬自组装纳米前药与末端叠氮的烃基长链在溶剂中于30~80℃反应得到两亲性树状分子布洛芬自组装纳米前药,其中两亲性树状分子布洛芬自组装纳米前药与叠氮末端的烃基长链的摩尔比为1:1.0~2:1.0。
9.根据权利要求4所述的布洛芬纳米前药包载抗肿瘤药物的双药共递送纳米胶束的制备方法,其特征在于步骤(4)的具体过程为:将两亲性树状分子布洛芬自组装纳米前药溶于有机溶剂形成浓度为1.0~25.0mg/mL的两亲性树状分子布洛芬自组装纳米前药有机溶液,随后将两亲性树状分子布洛芬自组装纳米前药有机溶液滴加到水溶液中,再除去有机溶剂得到含有平均粒径为7-400nm纳米颗粒的自组装纳米胶束。
10.权利要求1~3中任意一项所述布洛芬纳米前药包载抗肿瘤药物的双药共递送纳米胶束在制备抗肿瘤药物靶向递送及抑制恶性肿瘤细胞增殖的靶向抗肿瘤药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310499610.XA CN116637072A (zh) | 2023-05-04 | 2023-05-04 | 一种布洛芬纳米前药包载抗肿瘤药物的双药共递送纳米胶束及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310499610.XA CN116637072A (zh) | 2023-05-04 | 2023-05-04 | 一种布洛芬纳米前药包载抗肿瘤药物的双药共递送纳米胶束及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116637072A true CN116637072A (zh) | 2023-08-25 |
Family
ID=87622120
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310499610.XA Pending CN116637072A (zh) | 2023-05-04 | 2023-05-04 | 一种布洛芬纳米前药包载抗肿瘤药物的双药共递送纳米胶束及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116637072A (zh) |
-
2023
- 2023-05-04 CN CN202310499610.XA patent/CN116637072A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111298132B (zh) | 一种树状分子吉西他滨自组装纳米前药及其制备方法和应用 | |
US9745273B2 (en) | Phenazine derivatives as anti-neoplastic agents and anti-infective agents | |
CN111484501A (zh) | 羟基喜树碱亚油酸酯小分子前药及其自组装纳米粒的构建 | |
CN112089845B (zh) | 紫杉烷类药物-阿霉素前药自组装纳米粒及其应用 | |
CN111718395B (zh) | 一种前药激活化合物、前药体系及其制备方法和应用 | |
CN111135299A (zh) | 光敏剂-低氧激活前药一体化前药自组装纳米粒的构建 | |
CN110732027A (zh) | 一种刺激响应的靶向聚多糖超分子诊疗组装体及其制备方法 | |
CN108586551B (zh) | IR780-LA/CPT-ss-CPT纳米粒的制备与应用 | |
CN114796513B (zh) | 二硒键桥连多西他赛二聚体前药及其自组装纳米粒 | |
CN110452098A (zh) | 全羟基取代的四联苯芳烃、其水溶性磺化物及制备方法 | |
CN109306058A (zh) | 一种叶酸和三苯基膦共同修饰的普朗尼克共聚物及其制备方法和用途 | |
CN116637072A (zh) | 一种布洛芬纳米前药包载抗肿瘤药物的双药共递送纳米胶束及其制备方法和应用 | |
CN113461754B (zh) | 一种碱基修饰的阿霉素前药及其制备方法和应用 | |
CN103055321A (zh) | 一种聚乙二醇单甲醚-聚磷酸酯两嵌段共聚物及其阿霉素键合药 | |
CN112641760B (zh) | 二茂铁-黄连素/吲哚美辛@葡萄糖氧化酶@透明质酸纳米药物、制备方法与应用 | |
CN116120333B (zh) | 一种鬼臼毒素纳米前药及其制备方法与应用 | |
CN107823650B (zh) | 葡萄糖修饰的新型脑靶向磁性纳米粒的制备 | |
CN114796515B (zh) | 一种双重响应的聚乙二醇前药及其制备方法和应用 | |
WO2022227556A1 (zh) | 多西他赛-脂肪醇小分子前药及其自组装纳米粒的构建 | |
CN113018302B (zh) | 一种薯蓣皂苷元衍生物与dha自组装纳米粒的制备方法及应用 | |
CN110772643B (zh) | α-生育酚聚乙二醇琥珀酸酯修饰的强心苷类化合物前药 | |
CN114196028B (zh) | Pamam-tpgs及其制备方法与应用 | |
CN114276390B (zh) | 一种用于抗肿瘤药物递送的二硫代氨基甲酸酯衍生物纳米药物及其制备方法与应用 | |
CN115192523B (zh) | 一种以苯硼酸酯为连接单元的雷公藤红素前药自组装纳米粒及其制备方法和应用 | |
CN114404585A (zh) | 一种基于血卟啉单甲醚糖基缀合物的光化一体载药纳米胶束及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |